The development of a new cancer drug at the University of Alberta shows both the promise and the challenges of drug development. Pacylex Pharmaceuticals, a U of A spinoff, is making incredible strides with its drug, zelenirstat – a potential game-changer for treating blood and solid tumour cancers. But behind the exciting progress is the difficult, time-consuming journey of turning a lab discovery into a life-saving treatment. This path requires more than just innovative science; it’s a team effort that includes patients, doctors, researchers, and the support of generous donors and investors.
In its first Phase 1 human trials, zelenirstat demonstrated promise by targeting a process that allows cancer cells to grow uncontrollably. But what makes this treatment even more groundbreaking is a second mechanism that prevents cancer cells from using oxygen, effectively “suffocating” them and halting their growth. Early results have shown it could benefit patients with both blood and solid tumour cancers, offering a new hope to those who have run out of options with conventional treatments.
However, bringing zelenirstat to patients requires overcoming one of the biggest challenges in drug development: securing the funding necessary for the next phases of clinical trials. Phase 2 and 3 trials are critical to prove the drug’s safety and effectiveness across a larger group of patients. It is estimated it will cost about $100 million to fund the necessary trials to gain regulatory approval and make zelenirstat a treatment that can help cancer patients worldwide.
The development of zelenirstat is not just a success story of scientific innovation – it’s a story of collaboration. As co-founder John Mackey puts it: “It’s time-consuming, it’s difficult, and it requires a team that includes good scientists, willing patients, and clinicians who are devoted to advancing their field. Every step forward has been a collective effort, supported by a network of donors, investors and, most importantly, patients who are willing to take part in clinical trials to help move the needle in cancer treatment.”
As Pacylex continues its journey to Phase 2 and 3 trials, the company is also facing growing competition from other companies developing similar treatments. This competition, while challenging, helps validate the potential of zelenirstat and shows the urgent need for new cancer treatments. It also emphasizes the importance of continued investment in groundbreaking research and clinical trials.
For zelenirstat to become a reality for cancer patients, continued support is crucial. Clinical trials depend on patient participation, and funding is key to ensuring that this treatment can reach those who need it most.
See the full article to learn more about this exciting new treatment and the road ahead.
For more information about the drug approval system, drug access, and patient support programs in Canada, visit the Treatment Access page of CLL Canada website.